Nyheter | Spotlight
Hem

Press release from Companies

Publicerat: 2018-08-24 14:35:17

EQL Pharma AB: Anders Månsson appointed new member of the Board of EQL Pharma AB

Anders Månsson has extensive experience from the pharmaceutical industry and has worked in senior positions in mid-size pharma companies, including Ferring and LEO Pharma. He has worked internationally - from London, Lausanne and Copenhagen, but since last year he has an operative role as President & CEO and shareholder in Lund-based Longboat Explorers AB, a stem cell focused company. Anders is also a member of the Board of Respiratorius AB, as well as Chairman of the Board of CanImGuide Therapeutics AB.

"I know Anders since several years as we have worked together in the Boards of Respiratorius and Longboat. We complement each other and work well together. With EQL's forthcoming expansion, Anders's experience becomes increasingly relevant to the Board of EQL", says Christer Fåhraeus.

"It will be exciting to get to know EQL Pharma in depth. I believe there are many opportunities for expanding the business, especially outside Sweden, and I think that my experience can benefit EQL going forward in several ways", says Anders Månsson.

Anders Månsson was formally elected at EQL Pharmas AGM on August 22nd, 2018.

Links to news history of Anders Månsson:

https://www.8till5.se/2017-06-09/lakemedelshojdare-gar-till-skansk-stamcellsstartup
https://www.8till5.se/2015-11-28/skaningen-som-fixade-leo-pharmas-jatteaffar


For further information, please contact: Christer Fåhraeus CEO EQL Pharma AB (publ) Phone: +46 (0) 705 - 60 90 00 E-mail: christer.fahraeus@eqlpharma.com Website: www.eqlpharma.com 
About EQL Pharma  EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets 9 niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (8) people and is listed on Spotlight Stock Market. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China. 

Läs mer om EQL Pharma AB